alternative RNA splicing

alternative RNA splicing

[ȯl¦tər·nəd·iv ¦är¦en′ā ‚splīs·iŋ]
(cell and molecular biology)
A process in gene expression that enables the production of multiple forms of messenger ribonucleic acid (mRNA) from a single RNA transcript, thus enabling the production of multiple forms of protein from one gene.
References in periodicals archive ?
PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1].
The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop diagnostic tests and innovative treatments for neurodegenerative diseases, especially Alzheimer's disease and cancers.
ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing and a contract research service laboratory for gene expression analysis.
ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer.
ExonHit Therapeutics is a world-leading company in developing novel pharmaceuticals and diagnostics from its unique understanding of alternative RNA splicing, the process by which a single gene can lead to several proteins.
There is a second way to generate diversity, called alternative RNA splicing.
Nadal-Ginard found the alternative RNA splicing in a muscle protein serendipitously, he says.
These arrays cover whole genomes and monitor known and predicted alternative RNA splicing events.
The Human Genome Wide SpliceArray[TM] monitors known and predicted alternative RNA splicing events in close to 21,000 human genes and is used in the Company's biomarker and target discovery process.
The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for Alzheimer's disease and cancer indications.
The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications.
Full browser ?